Viking Therapeutics [VKTX] vs Vertex [VRTX] Detailed Stock Comparison
Viking Therapeutics
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Viking Therapeutics wins in 5 metrics, Vertex wins in 10 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Viking Therapeutics | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -25.44 | 27.77 | Viking Therapeutics |
| Price-to-Book Ratio | 3.44 | 5.83 | Viking Therapeutics |
| Debt-to-Equity Ratio | 0.11 | 8.89 | Viking Therapeutics |
| PEG Ratio | -0.13 | -0.22 | Vertex |
| EV/EBITDA | -31.00 | 19.86 | Viking Therapeutics |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | 0.00% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -19.99% | 22.77% | Vertex |
| Return on Assets (TTM) | -14.99% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-87.79M | $-978.00M | Viking Therapeutics |
| 1-Year Return | -59.77% | -17.90% | Vertex |
| Price-to-Sales Ratio (TTM) | N/A | 8.77 | N/A |
| Enterprise Value | $4.67B | $95.33B | Vertex |
| EV/Revenue Ratio | N/A | 8.35 | N/A |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-1.54 | $14.07 | Vertex |
| Beta (Stock Volatility) | 0.67 | 0.44 | Vertex |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Viking Therapeutics vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Viking Therapeutics | 1.40% | -35.00% | -18.94% | -6.17% | -10.89% | -36.72% |
| Vertex | -0.57% | 0.62% | -15.94% | -8.94% | -17.95% | -2.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Viking Therapeutics | -59.77% | 680.78% | 280.67% | 313.35% | 185.71% | 185.71% |
| Vertex | -17.90% | 40.27% | 46.36% | 194.76% | 1,046.94% | 2,164.30% |
Performance & Financial Health Analysis: Viking Therapeutics vs Vertex
| Metric | VKTX | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $2.74B | $100.19B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 11,325,400 | 2,534,760 |
| 90 Day Avg. Volume | 6,307,173 | 1,946,450 |
| Last Close | $26.02 | $395.21 |
| 52 Week Range | $18.92 - $81.73 | $362.50 - $519.88 |
| % from 52W High | -68.16% | -23.98% |
| All-Time High | $99.41 (Feb 26, 2024) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -73.83% | -23.98% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.12% |
| Quarterly Earnings Growth | N/A | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | 0.00% | 0.39% |
| Return on Equity (TTM) | -0.20% | 0.23% |
| Debt to Equity (MRQ) | 0.11 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.08 | $67.02 |
| Cash per Share (MRQ) | $3.59 | $24.90 |
| Operating Cash Flow (TTM) | $-152,535,008 | $3.85B |
| Levered Free Cash Flow (TTM) | $-102,103,128 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Viking Therapeutics vs Vertex
| Metric | VKTX | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -25.44 | 27.77 |
| Forward P/E | -16.13 | 20.82 |
| PEG Ratio | -0.13 | -0.22 |
| Price to Sales (TTM) | N/A | 8.77 |
| Price to Book (MRQ) | 3.44 | 5.83 |
| Market Capitalization | ||
| Market Capitalization | $2.74B | $100.19B |
| Enterprise Value | $4.67B | $95.33B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 8.35 |
| Enterprise to EBITDA | -31.00 | 19.86 |
| Risk & Other Metrics | ||
| Beta | 0.67 | 0.44 |
| Book Value per Share (MRQ) | $7.08 | $67.02 |
Financial Statements Comparison: Viking Therapeutics vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VKTX | VRTX |
|---|---|---|
| Revenue/Sales | $0 | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $60.15M | $978.40M |
| Operating Income (EBIT) | $-74.57M | $1.15B |
| EBITDA | $-74.47M | $1.34B |
| Pre-Tax Income | $-65.56M | $1.28B |
| Income Tax | N/A | $250.10M |
| Net Income (Profit) | $-65.56M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VKTX | VRTX |
|---|---|---|
| Cash & Equivalents | $37.94M | $4.67B |
| Total Current Assets | $866.02M | $10.01B |
| Total Current Liabilities | $19.57M | $3.78B |
| Long-Term Debt | $502,000 | $1.65B |
| Total Shareholders Equity | $846.92M | $16.50B |
| Retained Earnings | $-533.54M | $10.25B |
| Property, Plant & Equipment | $0 | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VKTX | VRTX |
|---|---|---|
| Operating Cash Flow | $-33.91M | $404.90M |
| Capital Expenditures | N/A | $-40.70M |
| Free Cash Flow | $-52.33M | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | VKTX | VRTX |
|---|---|---|
| Shares Short | 28.70M | 4.36M |
| Short Ratio | 7.30 | 4.04 |
| Short % of Float | 0.31% | 0.02% |
| Average Daily Volume (10 Day) | 11,325,400 | 2,534,760 |
| Average Daily Volume (90 Day) | 6,307,173 | 1,946,450 |
| Shares Outstanding | 111.57M | 256.94M |
| Float Shares | 219.96M | 255.58M |
| % Held by Insiders | 0.02% | 0.00% |
| % Held by Institutions | 0.69% | 0.99% |
Dividend Analysis & Yield Comparison: Viking Therapeutics vs Vertex
| Metric | VKTX | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |